Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Cancer evasion of the immune system: the fundamentals

Checkpoint blockade: a concept or already a reality?

Emerging pathways in immunotherapy

Myeloma genomics and Immuno-oncology

Upcoming trends in myeloma therapy

Recent advances in mantle cell lymphoma: Expert panel discussion

Lecture: Current use of systemic therapies in localised disease